NASDAQ · TCRT
Alaunos Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TCRT: Nov 13, 2026
Alaunos Therapeutics, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.55.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 23, 7:22 PM EDTAlaunos Therapeutics, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement of $2,500,000Alaunos Therapeutics, Inc. announced that on October 22, 2026, it received a letter from Nasdaq's Office of General Counsel advising that the Staff has confirmed that the Company has regained compliance with the Stockholders' Equity Requirement. This requirement, under Nasdaq Lis
- Fintel · Oct 22, 3:38 AM EDTAlaunos Therapeutics, Inc. Believes It Regained Nasdaq Compliance Following $350.0 million FinancingAlaunos Therapeutics, Inc. announced that it believes it has regained compliance with the Nasdaq minimum stockholders' equity requirement of $2,500,000. Previously, on April 9, 2026, the company received a deficiency letter from Nasdaq because its stockholders' equity was $2,153,
- RTTNews · Oct 13, 9:32 AM EDTParagon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up(RTTNews) – Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed its acquisition of Velaris Therapeutics, Inc., a biotechnology company focused on pulmonary
- RTTNews · Sep 18, 9:13 AM EDTAlaunos Prices $1.12M Registered Direct Offering(RTTNews) – Alaunos Therapeutics, Inc. (TCRT) announced that it entered into definitive agreements with institutional investors for a registered direct offering of 380,469 shares of common stock and pre-funded warrants to purchase up to 386,654 shares.
- RTTNews · May 28, 4:11 AM EDTTop Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX(RTTNews) – Today's Top Gainers list features Q32 Bio, which announced a $55 million private placement financing; Soligenix, which is exploring the suitability of its ThermoVax platform to fight the Bundibugyo strain of Ebola virus; P3 Health Partners, which recently reported str
- Zacks · Aug 31, 8:59 AM EDTJ&J (JNJ) Updates 2023 Guidance After Final Kenvue SeparationJohnson & Johnson JNJ provided an updated financial guidance for 2023, following the complete separation of its Consumer Health segment as a new publicly-traded company called Kenvue KVUE. J&J also updated its first-half f
- Zacks · Aug 28, 10:45 AM EDTMerck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer StudyMerck MRK and partner Eisai announced that they are closing a study evaluating a combination of Merck’s blockbuster PD-1 inhibitor, Keytruda and Eisai’s TKI inhibitor, Lenvima for first-line treatment of recurrent or metastatic he
- Zacks · Aug 16, 10:20 AM EDTAlaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%Shares of Alaunos Therapeutics TCRT plummeted 64.7% on Aug 15, after management announced its decision to discontinue the development of its sole clinical-stage asset, which was being developed across multiple solid tumor indicati
- Zacks · May 15, 8:18 AM EDTHere's Why You Should Add Pacira (PCRX) Stock to Your PortfolioPacira Biosciences PCRX is a Parsippany, NJ-based, specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are devel
- Zacks · Apr 6, 6:00 PM EDTAlaunos (TCRT) Stock Sinks As Market Gains: What You Should KnowIn the latest trading session, Alaunos (TCRT) closed at $0.60, marking a -1.64% move from the previous day. This change lagged the S&P 500's daily gain of 0.36%. At the same time, the Dow added 0.01%, and the tech-heavy Nasdaq gained 1.91%.
- Zacks · Mar 22, 6:00 PM EDTAlaunos (TCRT) Gains As Market Dips: What You Should KnowAlaunos (TCRT) closed at $0.50 in the latest trading session, marking a +1.02% move from the prior day. This move outpaced the S&P 500's daily loss of 1.65%. Elsewhere, the Dow lost 1.63%, while the tech-heavy Nasdaq lost 6.65%.
- Zacks · Mar 3, 9:36 AM ESTAlaunos (TCRT) to Report Q4 Earnings: What's in the Cards?We expect investors to focus on pipeline updates when Alaunos Therapeutics TCRT reports fourth-quarter 2022 results on Mar 7.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Alaunos Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.